Lineage Cell Therapeutics, Inc. Payments of Stock Issuance Costs
Lineage Cell Therapeutics, Inc. (LCTX) had Payments of Stock Issuance Costs of $2.30 million as of 2024-11-21, per its 10-Q filed 2025-05-13.
Financial Statements › Cash Flow › Financing Activities
us-gaap:PaymentsOfStockIssuanceCosts · last filed 2025-05-13
- Lineage Cell Therapeutics, Inc. payments of stock issuance costs for the quarter ending 2024-09-30 was $0.00, a 100.00% decline year-over-year.
- Lineage Cell Therapeutics, Inc. payments of stock issuance costs for the quarter ending 2024-06-30 was $1.00K, a 99.43% decline year-over-year.
- Lineage Cell Therapeutics, Inc. payments of stock issuance costs for the quarter ending 2024-03-31 was $112.00K.
- Lineage Cell Therapeutics, Inc. payments of stock issuance costs for the quarter ending 2023-12-31 was $0.00, a 100.00% decline year-over-year.
- Lineage Cell Therapeutics, Inc. payments of stock issuance costs for fiscal 2023 was $199.00K, a 87.74% increase from fiscal 2022.
- Lineage Cell Therapeutics, Inc. payments of stock issuance costs for fiscal 2022 was $106.00K.
| Period end | Payments of Stock Issuance Costs | Payments of Stock Issuance Costs 3 month | Payments of Stock Issuance Costs 6 month | Payments of Stock Issuance Costs 9 month | Payments of Stock Issuance Costs 12 month |
|---|---|---|---|---|---|
| 2024-11-21 | $2.30M 10-Q · filed 2025-05-13 | ||||
| 2024-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-14 | $1.00K derived: sum of 2 quarters · filed 2024-11-14 | $113.00K 10-Q · filed 2024-11-14 | $113.00K derived: sum of 4 quarters · filed 2024-11-14 | |
| 2024-06-30 | $1.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-08 | $113.00K 10-Q · filed 2024-08-08 | $113.00K derived: sum of 3 quarters · filed 2024-08-08 | $138.00K derived: sum of 4 quarters · filed 2024-11-14 | |
| 2024-03-31 | $112.00K 10-Q · filed 2024-05-09 | $112.00K derived: sum of 2 quarters · filed 2024-05-09 | $137.00K derived: sum of 3 quarters · filed 2024-11-14 | $311.00K derived: sum of 4 quarters · filed 2024-11-14 | |
| 2023-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-07 | $25.00K derived: sum of 2 quarters · filed 2024-11-14 | $199.00K derived: sum of 3 quarters · filed 2024-11-14 | $199.00K 10-K · filed 2024-03-07 | |
| 2023-09-30 | $25.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-14 | $199.00K derived: sum of 2 quarters · filed 2024-11-14 | $199.00K 10-Q · filed 2024-11-14 | $210.00K derived: sum of 4 quarters · filed 2024-11-14 | |
| 2023-06-30 | $174.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-08 | $174.00K 10-Q · filed 2024-08-08 | $185.00K derived: sum of 3 quarters · filed 2024-08-08 | ||
| 2023-03-31 | $0.00 10-Q · filed 2024-05-09 | $11.00K derived: sum of 2 quarters · filed 2024-05-09 | |||
| 2022-12-31 | $11.00K derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-07 | $106.00K 10-K · filed 2024-03-07 | |||
| 2022-09-30 | $95.00K 10-Q · filed 2023-11-09 | ||||
| 2016-09-30 | $410.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2016-11-04 | $1.51M 10-Q · filed 2016-11-04 | |||
| 2016-06-30 | $1.10M 10-Q · filed 2016-08-09 | ||||
| 2015-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2016-11-04 | $0.00 10-Q · filed 2016-11-04 | |||
| 2015-06-30 | $0.00 10-Q · filed 2016-08-09 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Aligos Therapeutics, Inc. (ALGS) | United States | $0.238B | -0.47 |
| SUTRO BIOPHARMA, INC. (STRO) | United States | $0.260B | -3.05 |
| Protalix BioTherapeutics, Inc. (PLX) | $0.221B | 9.87 | |
| ANAVEX LIFE SCIENCES CORP. (AVXL) | United States | $0.218B | -18.37 |
| Alector, Inc. (ALEC) | United States | $0.213B | -1.90 |
| Invivyd, Inc. (IVVD) | United States | $0.270B | -2.42 |
| PALISADE BIO, INC. (PALI) | United States | $0.275B | -11.41 |
| Compass Therapeutics, Inc. (CMPX) | United States | $0.204B | -5.35 |
| Lexeo Therapeutics, Inc. (LXEO) | United States | $0.278B | -4.19 |
| FATE THERAPEUTICS INC (FATE) | United States | $0.280B | -2.51 |